A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies

被引：0
|
作者：
Thieblemont, Catherine [1 ]
Stathis, Anastasios [2 ]
Inghirami, Giorgio [3 ]
Karlin, Lionel [4 ]
Morschhauser, Franck [5 ]
Gleeson, Mary [6 ,7 ]
Broussais, Florence [8 ]
Amorim, Sandy [1 ]
Salles, Gilles [4 ]
Facon, Thierry [5 ]
Cunningham, David [6 ,7 ]
Vey, Norbert [9 ]
Bourdel, Fabrice [10 ]
Herait, Patrice [11 ]
Zucca, Emanuele [2 ]
机构：
[1] Hop St Louis, AP HP, Paris, France
[2] Oncol Inst Southern Switzerland, Bellinzona, Switzerland
[3] Weill Cornell Med Coll, New York, NY USA
[4] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France
[5] CHRU Lille, Hop Claude Huriez, F-59037 Lille, France
[6] Royal Marsden Hosp, London SW3 6JJ, England
[7] Royal Marsden Hosp, Sutton, Surrey, England
[8] Inst J Paoli I Calmettes, F-13009 Marseille, France
[9] Inst J Paoli I Calmettes, Oncohematol EToH Dept, F-13009 Marseille, France
[10] Oncol Therapeut Dev, Clichy, France
[11] OncoEthix SA, Lausanne, Switzerland
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] BET Bromodomain Inhibitor OTX015 Affects the Expression of Micrornas Involved in the Pathogenesis of Diffuse Large B-Cell Lymphoma
    Cascione, Luciano
    Gaudio, Eugenio
    Bernasconi, Elena
    Tarantelli, Chiara
    Rinaldi, Andrea
    Testoni, Monica
    Bomben, Riccardo
    Gattei, Valter
    Kwee, Ivo
    Stathis, Anastasios
    Riveiro, Maria Eugenia
    Zucca, Emanuele
    Bertoni, Francesco
    [J]. BLOOD, 2014, 124 (21)
  • [22] In vitro evaluation of OTX015, a novel pan-BET-bromodomain (BET-BRD) inhibitor, as single agent and in combination with standard chemotherapy drugs in human leukemic cell lines
    Astorgues-Xerri, Lucile
    Vazquez, Ramiro
    Bekradda, Mohamed
    Cvitkovic, Esteban
    Herait, Patrice
    Raymond, Eric
    Riveiro, Mara E.
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [23] The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb
    Lu, Panpan
    Qu, Xiying
    Shen, Yinzhong
    Jiang, Zhengtao
    Wang, Pengfei
    Zeng, Hanxian
    Ji, Haiyan
    Deng, Junxiao
    Yang, Xinyi
    Li, Xian
    Lu, Hongzhou
    Zhu, Huanzhang
    [J]. SCIENTIFIC REPORTS, 2016, 6
  • [24] The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
    Boi, Michela
    Gaudio, Eugenio
    Bonetti, Paola
    Kwee, Ivo
    Bernasconi, Elena
    Tarantelli, Chiara
    Rinaldi, Andrea
    Testoni, Monica
    Cascione, Luciano
    Ponzoni, Maurilio
    Mensah, Afua Adjeiwaa
    Stathis, Anastasios
    Stussi, Georg
    Riveiro, Maria Eugenia
    Herait, Patrice
    Inghirami, Giorgio
    Cvitkovic, Esteban
    Zucca, Emanuele
    Bertoni, Francesco
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (07) : 1628 - 1638
  • [25] DOSE OPTIMIZATION OF MK-8628 (OTX015), A SMALL MOLECULE INHIBITOR OF BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEINS, IN PATIENTS WITH RECURRENT GLIOBLASTOMA
    Hottinger, A. F.
    Sanson, M.
    Moyal, E.
    Delord, J.
    Rezai, K.
    Leung, A.
    Perez, S.
    Bekradda, M.
    Lachaux, N.
    Chinot, O.
    [J]. NEURO-ONCOLOGY, 2016, 18 : 56 - 56
  • [26] The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb
    Panpan Lu
    Xiying Qu
    Yinzhong Shen
    Zhengtao Jiang
    Pengfei Wang
    Hanxian Zeng
    Haiyan Ji
    Junxiao Deng
    Xinyi Yang
    Xian Li
    Hongzhou Lu
    Huanzhang Zhu
    [J]. Scientific Reports, 6
  • [27] Cellular pharmacokinetics and molecular pharmacodynamics studies of the BRD-BET inhibitor OTX015 in sensitive and resistant leukemic cell lines
    Odore, E.
    Astorgues-Xerri, L.
    Bekradda, M.
    Cvitkovic, E.
    Herait, P.
    Lokiec, F.
    Rezai, K.
    Riveiro, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 189 - 189
  • [28] A phase lb trial with MK-8628/OTX015, a small molecule inhibitor of bromodomain (BRD) and extra-terminal (BET) proteins, in patients with selected advanced solid tumors
    Massard, C.
    Soria, J. C.
    Stathis, A.
    Delord, J. P.
    Awada, A.
    Peters, S.
    Lewin, J.
    Bekradda, M.
    Rezai, K.
    Zeng, Z.
    Azher, H.
    Perez, S.
    Siu, L.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 69 : S2 - S3
  • [29] Dose optimization of MK-8628 (OTX015), a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins, in patients (pts) with recurrent glioblastoma (GB)
    Hottinger, Andreas Felix
    Sanson, Marc
    Moyal, Elizabeth
    Delord, Jean-Pierre
    De Micheli, Rita
    Rezai, Keyvan
    Leung, Abraham C. F.
    Perez, Susan
    Bekradda, Mohamed
    Lachaux, Nicolas
    Lokiec, Francois Marc
    Chinot, Olivier L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] The BET bromodomain inhibitor OTX015 shows synergy with several anticancer agents in preclinical models of mantle cell lymphoma (MCL) and multiple myeloma (MM)
    Bernasconi, E.
    Tarantelli, C.
    Gaudio, E.
    Kwee, I.
    Stathis, A.
    Riveiro, E.
    Herait, P.
    Cvitkovic, E.
    Zucca, E.
    Bertoni, F.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 184 - 184
12345